💊 #FDA Drug Approvals — September 2026
#Lirafugratinib, #Isembyld & #Zanvastro bring new approaches targeting FGFR, myostatin & RNA.

#Sevabertinib, #Camizestrant, #Imlunestrant, #Aqneursa & #Joenja expand therapeutic options across cancer, rare diseases & genetic disorders.

#FDA approves #Joenja for children with activated phosphoinositide 3-kinase delta syndrome (APDS): is the first treatment approved for #APDS, a rare #primary #immunodeficiency. www.healio.com/news/...

🚨The #FDA has approved #Joenja (leniolisib) as the first treatment for children aged 4-11 years with activated phosphoinositide 3-kinase delta syndrome (#APDS), a rare genetic disorder affecting the immune system.
📊Phase 3 study showed reduced lymphadenopathy and increased naïve B cells.